ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / ENTA / options
ARCT (25) PRLD (33) TTRX (38) IRD (23) ⌘ Pro Terminal β†’

Enanta Pharmaceuticals Inc. (ENTA) Options Positioning, Max Pain & Unusual Sweeps

$10.43 -2.61% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $10.36

Enanta Pharmaceuticals Inc. (ENTA) carries a Roarable Rating of E (Strong Sell) with 20/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E β€’ RED ALERT Cap $311.9M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ENTA Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is ENTA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, Enanta Pharmaceuticals Inc. (NASDAQ: ENTA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 20/100 at a spot price of $10.43 (-2.61% 1D, market cap $311.9M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 4/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, ENTA ranks #977 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does ENTA compare to ARCT and PRLD in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ENTA carries a Roarable E (20/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, ARCT (Arcturus Therapeutics Holdings Inc.) holds a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $313.5M) and PRLD (Prelude Therapeutics Incorporated) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $309.6M). Among the 5-stock peer group, ENTA leads on earnings multiple (N/A) while TTRX leads on capital efficiency (-28.3% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ENTA?
β–Ό

Per ENTA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0001177648), Enanta Pharmaceuticals Inc. generated $65.3M in revenue (-3.4% YoY), -$81.9M in net income, and -$32.2M in free cash flow against $329.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $10.36 (-0.66%)🧬 Dilution Drag (+2.48% YoY Shares)βš™οΈ Cash Engine: 5/20 (E) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (20/100 Β· E) historically underperformed SPY in 71% of rolling 90-day windows (-11.8% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ E
025507510020
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E Β· Rk E
Cash (5)Whales (3)SEC (5)Macro (4)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-17.1% Base Target
$18 Bull$9 Base$7 Bear
πŸ“¬ FREE ENTA RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for ENTA)Realized 20D OHLCV Swing Band: Β±11.5%
Deterministic 5-Pillar Attribution (20/100 Composite)
πŸ” WHY ENTA SCORES 20/100 (E) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Cash Engine Quality+5/20 pts (25% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

β–² #2 Bullish Driver: SEC 10-K Forensic Risk+5/20 pts (25% of score)

Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) β€’ Piotroski F-Score 3/9

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
28
Grade E$11.52+1.3% Next Q
Q2 (-2Q)
25
Grade E$11.67+4.4% Next Q
Q3 (-1Q)
23
Grade E$12.18-14.4% Next Q
Current
20
Grade E$10.43-11.8% Hist 90D Ξ±
Trajectory: E (28) β†’ E (20)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a ENTA Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While ENTA currently carries a cautious 20/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($12.42) and Max Pain ($10.95) forces dealer call-delta covering toward $18.01.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ENTAβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œENTA Beats Next Quarter EPS Consensus (Dec 29, 2026) & Holds Above 200D SMA”
YES 20%NO 80%Trade / Inspect Odds β†’
CALL VS. PUT WHALE SHARE
β€” (No Active Options Snapshot)
Put/Call Ratio: β€” (No Active Options Snapshot)
MAX-PAIN EXPIRATION MAGNET
β€” (No Active Options Snapshot)
No active options chain max-pain snapshot on file
HISTORICAL 20D VOLATILITY SWING
Β±11.5%
Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (ENTA)

β€” (No Active Options Snapshot) β€” No unusual CBOE strike concentration anomalies recorded in the current database snapshot for ENTA.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

πŸ† Enter Free $100K Paper Arena β†’
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ENTA)

  • βœ“Walkthrough of ENTA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
ENTA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -28.27%β–Ό SUPPORT BREAKDOWN
2026-11-03O $11.15H $11.15L $10.43C $10.43VOL 202.3K
RES: $14.44SUP: $10.48SMA50: $12.42SMA200: $13.17
$16.32$14.72$13.13$11.53$9.94RES $14.44SUP $10.48$10.432026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ENTA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ ENTA Butterfly Map β†’ + Track ENTA β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -3.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ENTA today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for ENTA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ENTA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ENTA)

Health Care Rank #977 of 1015 βš”οΈ ARCT vs ENTA Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (ENTA vs. ARCT, PRLD, TTRX, IRD)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Enanta Pharmaceuticals Inc. (ENTA) ranks #977 by composite RQD confidence (20/100, grade E) and #510 by equity capitalization ($311.9M). Within this direct 5-issuer industry benchmark cohort, ENTA leads on earnings valuation at N/A trailing P/E, while TTRX leads on capital efficiency and profitability with -28.3% ROIC and β€” gross margin. TTRX currently holds the highest overall quantitative score in the immediate peer group at 38/100 (D-) compared with ENTA at 20/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ENTA ACTIVE
Enanta Pharmaceuticals Inc.
E 20/100 β€” β€” -35.0% -2.61% $311.9M Benchmark Subject
ARCT
Arcturus Therapeutics Holdings Inc.
E 25/100 β€” β€” -35.0% -13.96% $313.5M /arct-vs-enta β†’
PRLD
Prelude Therapeutics Incorporated
E 33/100 β€” β€” -35.0% -1.03% $309.6M /prld-vs-enta β†’
TTRX
Turn Therapeutics Inc.
D- 38/100 β€” β€” -28.3% -7.48% $318.5M /ttrx-vs-enta β†’
IRD
Opus Genetics Inc.
E 23/100 β€” β€” -35.0% +0.82% $305.3M /ird-vs-enta β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-09-30 β€’ CIK 0001177648 β†—

In its most recent audited fiscal period (FY2025, filed 2025-09-30), Enanta Pharmaceuticals Inc. (ENTA) reported GAAP revenue of $65.3M (-3.4% vs. FY2024 revenue of $67.6M , and -17.5% cumulative change since FY2023) , GAAP net income of -$81.9M, operating cash flow of -$19.3M, and free cash flow of -$32.2M (+66.7% YoY). On the balance sheet, ENTA closed FY2025 with $329.5M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-09-30 $65.3M -$81.9M -$19.3M -$32.2M $329.5M β€”
FY2024 (FY) 2024-09-30 $67.6M -$116.0M -$78.8M -$96.7M $348.6M β€”
FY2023 (FY) 2023-09-30 $79.2M -$133.8M -$103.2M -$103.2M β€” β€”

3. ENTA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ENTA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Enanta Pharmaceuticals Inc. (NASDAQ: ENTA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 20/100 at a spot price of $10.43 (-2.61% 1D, market cap $311.9M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 4/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, ENTA ranks #977 in composite RQD confidence.

How does ENTA compare to ARCT and PRLD in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ENTA carries a Roarable E (20/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, ARCT (Arcturus Therapeutics Holdings Inc.) holds a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $313.5M) and PRLD (Prelude Therapeutics Incorporated) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $309.6M). Among the 5-stock peer group, ENTA leads on earnings multiple (N/A) while TTRX leads on capital efficiency (-28.3% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ENTA?

Per ENTA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0001177648), Enanta Pharmaceuticals Inc. generated $65.3M in revenue (-3.4% YoY), -$81.9M in net income, and -$32.2M in free cash flow against $329.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ENTA trading relative to its 50-day, 200-day, and 52-week technical levels?

ENTA last traded at $10.43 (-2.61% on volume of 350,523 shares), positioning the stock -16.02% below its 50-day simple moving average ($12.42) and -20.80% below its 200-day simple moving average ($13.17). Across its 52-week range of $10.22 to $17.15, ENTA sits at the 3.0% percentile with a 14-day RSI of 38.6 (NEUTRAL RANGE) and an implied next-earnings move of Β±11.5% ($9.23 to $11.63).

Direct Sub-Reports: ENTA RQD Cockpit ENTA 12M Forecast ENTA Earnings & Move ENTA Dividends & DRIP ENTA Insiders & 13F ENTA Whale Options ENTA Profit Sankey ENTA News & Why
ROARABLE RATING BRIEF β€’ RQD 20/100 (E) βœ“ SEC XBRL & RQD VERIFIED

ENTA β€” Enanta Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-09-30

1. Roarable Rating Brief: What This Means to a Prospective Investor

Enanta Pharmaceuticals Inc. (ENTA) earns a live Roarable RQD composite score of 20/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $10.43 (-2.61% 1D, market capitalization $311.9M).

  • Fundamental Cash Engine (5/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of β€”, operating margin of -60.0%, and free cash flow yield of -9.91%.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (4/20) + Forensic Balance Sheet (5/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Enanta Pharmaceuticals Inc. (ENTA) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. The market capitalization is $0.3B. Per the recent news wire, the company is developing an antiviral candidate for respiratory virus treatment in high-risk adults.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-09-30), Enanta Pharmaceuticals Inc. (ENTA) reported $65.3M in annual revenue (up from $67.6M in FY2024, -3.4% YoY) and -$81.9M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($79.2M revenue, -$133.8M net income) through FY2025, ENTA scaled operating cash flow to -$19.3M and free cash flow to -$32.2M, backed by $329.5M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (E β€’ RQD 20/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -9.91% and institutional whale pillar of 3/20. With Fundamental Cash Engine at 5/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $10.22 – $17.15 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), ENTA carries a macro regime beta of 1.00 and gross margin of β€”.

  • Key Question #1: Can ENTA sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $65.3M and free cash flow of -$32.2M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is ENTA's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

ENTA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Enanta Pharmaceuticals Inc. (ENTA) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to ENTA Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ENTA Bull vs. Bear Conversation Board β€” What's Your Call at $10.43?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ENTA 🐻 33% BEARISH CONVICTION
1. Pick Your Side on ENTA:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
SI SiliconVal_Bull RQD DEBATE OPENER β€’ Growth & Tech Investor πŸ‚ BULLISH 🎯 Target: $12.96 (+21.0%)
πŸ“Œ Pinned Debate

A scheduled RSV data presentation and antiviral trial in high-risk adults could re-rate the stock if results are positive.

A scheduled RSV data presentation and antiviral trial in high-risk adults could re-rate the stock if results are positive.. When you look under the hood at ENTA, Fundamental Cash Engine is 5/20 with 0.0% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (3/20) has been quietly accumulating below $17.15. My 12M target is $12.96.

EarningsSniper πŸ‚ BULL

Both sides have a point here β€” ENTA's 5/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

FA FadeTheHype RQD DEBATE OPENER β€’ Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $8.35 (-22.0%)
Spot @ $10.71

Negative ROIC of -35%, negative FCF yield of -9.91%, Altman Z of 0.2, and falling reported cash point to forensic distress risk.

Here is the bear case nobody on the bull side wants to address on ENTA: Negative ROIC of -35%, negative FCF yield of -9.91%, Altman Z of 0.2, and falling reported cash point to forensic distress risk.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.

LIVE TAPE